As a result of these finding a Phase I/II trial (NCT04849910) has been initiated to establish the safety of using trem‐cel as an allograft followed by GO maintenance therapy for patients with CD33+ AML or MDS who are at high risk of relapse and undergoing HCT. The gene discussed is CD33; the disease is acute myeloid leukemia.